All In Biotech

NDA 020405 · Advanz Pharma

Lanoxin

Digoxin · Oral · Cardiac Glycoside

Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Sep 30, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

275

14 Phase 3, 12 recruiting

FAERS reports

71,872

59,472 serious, 13,846 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2024.

LANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults LANOXIN is indicated for the treatment of mild to moderate heart failure in adults. LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients LANOXIN increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults LANOXIN is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation.

Mechanism: All of digoxin’s actions are mediated through its effects on Na-K ATPase. This enzyme, the “sodium pump,” is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin causes increased availability of intracellular calcium in the myocardium and conduction system, with consequent increased inotropy, increased automaticity, and reduced conduction velocity indirectly causes parasympathetic stimulation of the autonomic nervous system, with consequent effects on the sino-atrial (SA) and...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 30, 1997 Original approval · Type 7 - Drug Already Marketed without Approved NDA Review
6 products under this application
  • LANOXIN · DIGOXIN 0.1875MG · TABLET, ORAL · Discontinued
  • LANOXIN · DIGOXIN 0.0625MG · TABLET, ORAL · Prescription · TE AB
  • LANOXIN · DIGOXIN 0.5MG · TABLET, ORAL · Discontinued
  • LANOXIN · DIGOXIN 0.25MG · TABLET, ORAL · Prescription · TE AB
  • LANOXIN · DIGOXIN 0.125MG · TABLET, ORAL · Prescription · TE AB
  • LANOXIN · DIGOXIN 0.375MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Digoxin" as an intervention, any sponsor and status, largest first.

All 275 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea6,218
  • nausea4,866
  • dizziness4,566
  • fatigue4,288
  • atrial fibrillation4,066
  • diarrhoea3,896
  • asthenia3,662
  • death3,471
  • vomiting3,443
  • hypotension3,258
  • cardiac failure congestive3,144
  • pain3,062

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,671
20052,602
20062,533
20072,008
20084,394
20093,558
20103,377
20114,017
20123,946
20133,401
20144,322
20154,309
20164,283
20174,071
20183,910
20193,317
20202,990
20212,278
20221,862
20232,305
20242,178
20252,084
20261,449

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lanoxin* (Digoxin)

2024 spending

$967K

Beneficiaries

214

972 claims

Per beneficiary

$4,518

$16.32 per unit

View as table
YearSpending
2020$3,507,770
2021$3,102,461
2022$1,580,850
2023$1,214,352
2024$966,876

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,259 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.